Discovery Pipeline
  • aldosterone synthase inhibitor

    Aldosterone synthase inhibitor is a highly anticipated drug for cardio-metabolic indications. The drug will selectively inhibit synthesis of hormone aldosterone to manage deleterious effects of its excess.

    read more
  • anti-TB drug

    We are targeting a mycobacterial cytochromes P450 for treatment of tuberculosis infection, including its drug resistant forms.

    read more
  • pipeline potential

    Additional value generation activity via drug discovery in diversified indications and international scientific collaborations.

    read more
News and Events
05 May 2020
Target Medicals Group is a finalist of the Start-Up Stadium.
Target Medicals Group is among finalists of the Start-Up Stadium event at the 2020 BIO International Convention Digital
30 April 2020
AstraZeneca, Crystera and The University of Queensland enter into joint pioneering R&D collaboration
We are very excited about our new scientific collaboration with industry leaders!
02 March 2020
Target Medicals Group is a finalist of RESI Innovation challenge
Target Medicals Group is among finalists of global innovation competition within RESI Europe 2020.
All news and events